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Abstract: Metabolic flexibility is the capacity of an organism to adequately respond to changes in the
environment, such as nutritional input, energetic demand, etc. An important player in the capacity
of adaptation through different stages of metabolic demands is the mitochondrion. In this context,
mitochondrial dysfunction has been attributed to be the onset and center of many chronic diseases,
which are denoted by an inability to adapt fuel preferences and induce mitochondrial morphological
changes to respond to metabolic demands, such as mitochondrial number, structure and function.
Several nutritional interventions have shown the capacity to induce changes in mitochondrial
biogenesis/degradation, oxidative phosphorylation efficiency, mitochondrial membrane composition,
electron transfer chain capacity, etc., in metabolic inflexibility states that may open new target
options and mechanisms of action of bioactive compounds for the treatment of metabolic diseases.
This review is focused in three well-recognized food bioactive compounds that modulate insulin
sensitivity, polyphenols, ω-3 fatty acids and dietary fiber, by several mechanism of action, like
caloric restriction properties and inflammatory environment modulation, both closely related to
mitochondrial function and dynamics.
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1. Introduction
Life is the condition that distinguishes physical entities from inorganic matter, having processes,
such as the capacity for growth, reproduction, functional activity and continual change preceding
death. During all of these processes, life is regulated by biochemical reactions, named metabolism,
whereas with good environmental factors, it may be the adoption of the best metabolic pathway
for the achievement of the next lifetime step or induce a maintenance stage waiting for better
environmental conditions. At the cellular level, energy availability regulates most cellular functions.
Energy sensors, for example the AMP-activated protein kinase-α (AMPKα), activated by falling cellular
energy levels, acts to restore energy homoeostasis by switching on catabolic pathways that generate
ATP, while switching off anabolic pathways and other processes consuming ATP [1]. In this sense,
energy availability will predispose to cell survival, whereas energy unavailability will induce a static
stage and in the worst situation, if it continuous with time, cell death. Thus, metabolic flexibility,
the capacity of an organism, an organ or a single cell to adapt fuel oxidation to fuel availability
to meet cell energy demands, is an important feature in the maintenance of life [2]. However,
due to evolutionarily-acquired knowledge, the most common environmental condition in nature
is the one where energy availability is scarce, and most living organisms do not have the capacity
to induce metabolism adaptations in response to a continuous and prolonged energy availability
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stage. Translating this basic metabolism concept to the current human condition, most of the actual
chronic degenerative diseases have as a common factor the inability to adapt to an excess of energy
availability. For example, insulin resistance, the key defect in type 2 diabetes, is associated with a
low capacity to adapt fuel oxidation to fuel availability [3]. This results in lower glucose oxidation
during insulin-stimulated conditions and in a relative low activation of lipid catabolism, which further
supports the accumulation of ectopic fat and lipotoxicity with a deleterious effect on insulin signaling.
From a nutritional point of view, knowing that human metabolism is not well adapted to
prolonged energy availability, an increase in energy expenditure or reductions of energy intake
have been described as the main treatment objectives. However, most weight-loss programs for obese
patients are known to usually show low percentages of success in terms of weight loss and, most
importantly, in weight maintenance. This could be explained by several reasons:
(1) Not all organs and systems respond in a similar way to an increase or decrease in energy
availability. Differences are observed in insulin sensitivity in different organs during the
development from an insulin resistance stage to a clinically type 2 diabetes stage. It seems that
the onset of type 2 diabetes or other clinical complications are a consequence of the increase in the
number of organs with reduced insulin sensitivity. In the clinical setting, it is common to observe a
rapid shift from a non-pathological (subclinical) to a disease condition (Figure 1A) that is triggered
after exceeding a metabolic checkpoint where the organism is unable to maintain homeostasis.
For example, Figure 1B shows that the intake of a high-fat diet in mice is well regulated after
two months, until a possible accumulation of factors that triggers a disease condition observed
at Month 4 with a clinically-observed feature (unpublished observations); suggesting that, at a
certain point, the homeostatic compensation is overwhelmed, and pathological conditions could
be observed. Even though, it is interesting to note in the same Figure 1B that at four months of a
high-fat diet, the basal glucose levels are the same, although the organism is unable to maintain
normal glycemia levels; implying that, in stress conditions (glucose overload), the capacity of the
system to rapidly maintain homeostasis is compromised; albeit, finally, a homeostatic condition
is reached (fasting state).
(2) In the same way, in the clinical setting, the effects of a mild reduction in body weight induce a
rapid switch from a disease to a clinically non-pathological condition (Figure 1C). However, in
this respect, frailty from this condition is also observed if an increase in body weight is observed.
This implies that although most disease biomarkers are normalized during weight reduction
programs, the metabolic system is unstable and liable to return to a disease condition. In other
words, some organs still have metabolic inflexibility, explaining, in this way, the deleterious
effects of “yo-yo” dieting.
(3) The total recovery of the metabolic inflexibility condition will imply the normalization of
metabolic flexibility in all organs. Thus, combined treatments with multiple mechanisms of
action are required for a better handling of metabolic diseases.
To understand disease progression, it is important to know what a healthy metabolic capacity
constitutes. Individuals without metabolic diseases have the capacity to oxidize both carbohydrates
and lipid-based fuels and to transition between these substrates in response to hormones and substrate
signals. Thus, functional cellular defects in the energy transforming systems are likely to have profound
systemic effects on overall metabolic health. Mitochondrial deficiencies limit the capacity of oxidative
tissues to adapt fat oxidation to fat availability, leading to lipid accumulation in non-adipose tissue.
These lipids interfere with the insulin signaling pathway and represent one of the key aspects that
could contribute to metabolic imbalance [3].
There is increasing evidence for the concept of redox-driven alterations of mitochondrial function,
as well as mitochondrial reactive oxygen species generation as a key event for the development
of metabolic inflexibility. Diverse mitochondrial parameters vary between insulin-resistant and
insulin-sensitive subjects, such as mitochondrial number and structure [4]. However, it is also
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important to note that the differences in metabolic imbalances could not be described solely in terms
of mitochondrial quantity, rather by mitochondrial function. Many cells operate at basal levels that
only require a part of their total bioenergetics capability. The differences between ATP produced by
oxidative phosphorylation at basal and at maximal activity is termed reserve respiratory capacity [5].
Therefore, metabolic inflexibility limits the mitochondria from reaching their maximal respiratory
capacity, because of several factors that predispose to an excess of energy storage.
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Figure 1. The concept of metabolic inflexibility and disease related outcomes. (A) Scheme of high-
energy intake homeostatic regulation until a checkpoint, where energy storage systems are 
overloaded and subclinical and pathological conditions are observed. (B) Plasma glucose levels 
during a sub-cutaneous glucose tolerance test (2 g glucose/kg body weight) in controls and mice fed 
with a high-fat diet (34%) for two and four months. Insulin resistance, measured by means of blood 
glucose, is observed at four months of high-fat intake, whereas at two months, homeostatic 
compensation is still observed (unpublished observations). (C) Scheme of metabolic flexibility 
checkpoints in different organs for which, after passing organ-specific conditions, pathological 
features are observed. This explains the rapid change in metabolic flexibility after a weight reduction 
program and the yo-yo effect if the weight reduction is not maintained. 
2. Mitochondria Dynamic Regulation 
Mitochondria activity can be controlled through at least two major mechanism: acute ones, 
aimed at qualitatively modifying mitochondrial function, and longer-term transcriptional 
mechanisms, aimed at increasing mitochondrial number (Figure 2). 
Acute mechanisms affect the intrinsic ability of mitochondria to generate ATP per molecule of 
nutrient or per unit of time. The energy requirements fluctuate constantly, and the metabolism of 
ATP is regulated to avoid futile energy expenditure and to cater to the specific needs of different 
tissues. Short-term regulators of oxidative phosphorylation exert their control in response to sudden 
changes of ATP demand. 
The first level of regulation could be considered to occur by metabolic intermediates and 
substrate availability. As described by Chance and Williams in the 1950s, the metabolic states of 
mitochondria depend on substrate, oxygen and ADP levels [6]. The resting state of the mitochondria, 
defined as State 4, is where NADH is at 99% in the reduced form, and ADP is the rate limiting 
substance. If ADP is introduced into the system, ATP synthesis will be stimulated; O2 consumption 
will increase; and the rate limit will be determined by the activity of the respiratory chain; this last 
one is defined as State 3 or the “active state”. Other metabolism by-products, like ceramides, 
Figure 1. The concept of metabolic inflexibility and disease related outcomes. (A) Scheme of
high-energy intake homeostatic regulation until a checkpoint, where energy storage systems are
overloaded and sub linical and pathological conditions are observed. (B) Plasma glucose levels during
a sub-cutaneous glucose tolerance test (2 g glucose/kg body weight) in controls and mice fed with a
high-fat diet (34%) for two and four months. Insulin resistance, measured by means of blood glucose,
is observed at four months of high-fat intake, whereas at two months, homeostatic compensation is
still observed (unpublished observations). (C) Sc eme of metabolic flexibility checkpoints in different
organs for which, after passing organ-specific conditions, pathological features are observed. This
explains the rapid change in metabolic flexibility after a weight reduction program and the yo-yo effect
if the weight reduction is not maintained.
2. Mitochondria Dynamic Regulation
Mitochondria activity can be controlled through at least two major mechanism: acute ones, aimed
at qualitatively modifying mitochondrial function, and longer-term transcriptional mechanisms, aimed
at increasing mitochondrial number (Figure 2).
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Figure 2. Scheme of the mechanism of mitochondria functioning regulation. 
The electron transfer chain (ETC) has been demonstrated to be allosterically inhibited by ATP, 
whereby a futile overproduction of ATP is avoided [8]. Additionally, the catalytic activity of  
complex IV is regulated by the mitochondrial electric membrane potential [9], avoiding a 
hyperpolarization of the mitochondrial membrane and, thereby, avoiding excessive ROS production. 
Nitric oxide has also been demonstrated to regulate mitochondrial function at the level of  
cytochrome c oxidase by competing for the oxygen binding site of the enzyme [10]. 
In the same sense, post-translational modifications of ETC and ATP synthase have been 
demonstrated in several complexes’ catalytic activity. In fact, complex I and ATP synthase have been 
demonstrated to contain phosphorylation sites [11]. Additionally, other post-translational 
modifications, like protein acetylation, succinylation, glutathionylation and malonylation, have been 
described. Protein acetylation is a reversible mechanism linking the metabolic state and 
mitochondrial function. Upon fasting and high-fat feeding, the acetylation pattern of mitochondrial 
proteins strongly changes. For example, one week of high-fat diet enhanced silent mating type 
information regulation 2 homolog 3 (SIRT3) levels and prevented mitochondrial  
hyperacetylation [12], possibly to cope with the need to use fatty acid oxidation as the main path for 
energy production. Conversely, a prolonged high-fat diet decreased Sirt3 expression with the 
appearance of mitochondrial hyperacetylation and mitochondrial dysfunction, which suggests that, 
passing a homeostatic regulation capability threshold, dysfunction starts to emerge.  
Acute changes in mitochondria architecture have also been described, namely mitochondrial 
dynamics, where this involves fusion and fission processes. Cells under a well-fed condition maintain 
their mitochondria in a separated or fragmented state; while under fasting conditions, they tend to 
be in a fused state [13]. The main described regulators of the mitochondrial architecture for promoting 
fusion are mitofusin 1 (Mfn1), mitofusin 2 (Mfn2) and optic atrophy 1 (Opa1) proteins. Mitochondrial 
fission is regulated by mitochondrial fission factor (Mff) and dynamin-related protein 1 (Drp1). 
Changes in mitochondrial architecture addressed by fragmentation or fission processes may induce 
modifications in respiratory complex assembly, and the transition between fragmented and fused 
states allows mitochondria to reorganize and dispose of damaged elements through mitophagy. 
Notably, if the mitochondrial life cycle is attenuated, the accumulation of dysfunctional mitochondria 
will lead to an increase in oxidative stress that will lead to an increase of damaged mitochondria, 
entering a vicious circle. 
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Acute mechanisms affect the intrinsic ability of mitochondria to generate ATP per molecule of
nutrient or per unit of time. The energy requirements fluctuate constantly, and the metabolism of ATP
is regulated to avoid futile energy expenditure and to cater to the specific needs of different tissues.
Short-term regulators of oxidative phosphorylation exert their control in response to sudden changes
of ATP demand.
The first level of regulation could be considered to occur by metabolic intermediates and substrate
availability. As described by Chance and Williams in the 1950s, the metabolic states of mitochondria
depend on substrate, oxygen and ADP levels [6]. The resting state of the mitochondria, defined as
State 4, is where NADH is at 99% in the reduced form, and ADP is the rate limiting substance. If ADP
is introduced into the system, ATP synthesis will be stimulated; O2 consumption will increase; and the
rate limit will be determined by the activity of the respiratory chain; this last one is defined as State 3
or the “active state”. Other metabolism by-products, like ceramides, precursors for the predominant
sphingolipids in the cell, inhibit mitochondrial complex III activity [7] and may be the cause the
disruption of insulin sensitivity.
The electron transfer chain (ETC) has been demonstrated to be allosterically inhibited by ATP,
whereby a futile overproduction of ATP is avoided [8]. Additionally, the catalytic activity of complex
IV is regulated by the mitochondrial electric membrane potential [9], avoiding a hyperpolarization
of the mitochondrial membrane and, thereby, avoiding excessive ROS production. Nitric oxide has
also been demonstrated to regulate mitochondrial function at the level of cytochrome c oxidase by
competing for the oxygen binding site of the enzyme [10].
In the same sense, post-translational modifications of ETC and ATP synthase have been
demonstrated in several complexes’ catalytic activity. In fact, complex I and ATP synthase have
been demonstrated to contain phosphorylation sites [11]. Additionally, other post-translational
modifications, like protein acetylation, succinylation, glutathionylation and malonylation, have been
described. Protein acetylation is a reversible mechanism linking the metabolic state and mitochondrial
function. Upon fasting and high-fat feeding, the acetylation pattern of mitochondrial proteins strongly
changes. For example, one week of high-fat diet enhanced silent mating type information regulation 2
homolog 3 (SIRT3) levels and prevented mitochondrial hyperacetylation [12], possibly to cope with
the need to use fatty acid oxidation as the main path for energy production. Conversely, a prolonged
high-fat diet decreased Sirt3 expression with the appearance of mitochondrial hyperacetylation and
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mitochondrial dysfunction, which suggests that, passing a homeostatic regulation capability threshold,
dysfunction starts to emerge.
Acute changes in mitochondria architecture have also been described, namely mitochondrial
dynamics, where this involves fusion and fission processes. Cells under a well-fed condition maintain
their mitochondria in a separated or fragmented state; while under fasting conditions, they tend to be in
a fused state [13]. The main described regulators of the mitochondrial architecture for promoting fusion
are mitofusin 1 (Mfn1), mitofusin 2 (Mfn2) and optic atrophy 1 (Opa1) proteins. Mitochondrial fission
is regulated by mitochondrial fission factor (Mff) and dynamin-related protein 1 (Drp1). Changes in
mitochondrial architecture addressed by fragmentation or fission processes may induce modifications
in respiratory complex assembly, and the transition between fragmented and fused states allows
mitochondria to reorganize and dispose of damaged elements through mitophagy. Notably, if the
mitochondrial life cycle is attenuated, the accumulation of dysfunctional mitochondria will lead to
an increase in oxidative stress that will lead to an increase of damaged mitochondria, entering a
vicious circle.
Long-term regulators of oxidative phosphorylation could be considered as effectors involved in
the regulation of mitochondrial biogenesis. Although mitochondrial biogenesis is regulated by a large
number of coactivators and transcription factors, the proliferator-activated receptor coactivator-1α
(PGC-1α) plays a role as a master regulator of such processes, upregulating the activity of nuclear
respiratory factor 1 (NRF-1) and transcription factor A mitochondrial (TFAM); the two latter are
key for mitochondrial DNA (mtDNA) replication and transcription. PGC-1α activity is highly
regulated by post-transcriptional phosphorylation and acetylation. Reversible acetylation of PGC-1α
significantly modifies its transcriptional activity, and it seems to be primarily controlled by silent mating
type information regulation 2 homolog 1 (SIRT1), a nicotinamide adenine dinucleotide-dependent
deacetylase and AMPKα activated with high levels of AMP in relation to ATP [14].
Long-term regulators can also permanently change the properties of the mitochondrial respiration,
allowing mitochondrial differentiation, making them specialized for different cells and tissues.
For example, specific activity capacity in certain complexes has been observed in tissues with diverse
metabolic demands, which could be explained by the tissue-specific expression of ETC complexes’
isoforms. For example, complex IV isolated from cow lung has shown a 2.5-fold increased activity
compared to liver complex IV [15].
In addition to defining mitochondrial dynamics, it is important to give an overview about the
possible mechanism by which impairments in mitochondrial oxidative metabolism are observed.
The decrease in substrate oxidation may affect electron flow through the ETC, causing electron leakage
towards oxygen and the formation of superoxide. Superoxide and other ROS may damage several
mitochondrial and cellular components and potentially result in either mitophagy (removal of damaged
mitochondria) or, under high stress levels, apoptosis. The removal of mitochondria through mitophagy
or the accumulation of damaged mitochondria in the case where mitophagy is suppressed could reduce
the number of functioning mitochondria, resulting in decreased substrate oxidation. The reduced
oxidation of fuels, particularly fatty acids, results in lipid accumulation, including deposition of
metabolically-active lipid mediators, such as diacylglycerols and ceramides. Both have been shown to
inhibit insulin signaling, inducing an insulin resistance state that may affect other organs.
However, there is no consensus in the assessment of mitochondrial function. In this review, the
effects of polyphenols,ω-3 fatty acids and dietary fiber on mitochondrial function included studies that
assessed mitochondrial function by changes in mRNA levels of mitochondrial markers, alterations in
mitochondrial protein levels, enzymatic activity of key components of mitochondria-driven oxidation,
substrate oxidation, as well as changes in mitochondrial size and shape. Although, since there is not a
unique biomarker of its function, contradictory results are observed in the literature.
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3. Polyphenols and Mitochondria
Polyphenols are plant-derived compounds with pleiotropic biological activities. Currently, over
five hundred different polyphenols have been described in regularly-consumed foods. Although they
exhibit far more activities than antioxidant ones, they are most widely known as antioxidants and
therefore protector biomolecules against oxidative damage.
As mitochondria are the major cellular source of ROS, redox-active compounds can be targeted to
those organelles to modulate the levels of ROS and the processes they induce. However, as antioxidants,
it should be clear if the mechanism of action is derived by a direct interaction with oxidizing species
(redox potential) or by indirect pathways that may modulate metabolism or mitochondrial functioning,
therefore regulating the redox environment.
In the first case, cellular uptake of polyphenols is expected, and the rate of uptake will determine
their biological activity. However, the rate of polyphenols’ uptake in vivo is dependent on the
cell type, intracellular metabolism and rate of export [16]. Gut and hepatocyte uptake in vivo
could be demonstrated by the fact that polyphenol metabolites are found in plasma after their oral
intake. In vitro studies have also observed cellular uptake of flavonoids in T-cell lymphocytes, the
mitochondria being the principal reservoir compared to other cellular compartments [17]. In red
blood cells, it was described that quercetin is rapidly and avidly taken via a passive diffusion
mechanism, driven by flavonoid binding to hemoglobin and resulting in an almost quantitative
accumulation of the flavonoid [18]. In addition, in primary cultures of rat cerebellar granule neurons,
epigallocatechin-3-gallate, a major flavonoid component of green tea, 90%–95% of the polyphenol was
found accumulated in the mitochondrial fraction [19]. Nevertheless, the in vivo uptake of flavonoids
in adipose tissue, muscle and brain is not so clear. Moreover, on the basis of the discussion below,
large differences exist between the concentration of polyphenols required to exert an ROS-scavenging
action in vitro and those likely to be attained after their dietary consumption. The actual possibility
that polyphenols act in vivo through an ROS-scavenging mechanism has been increasingly questioned.
Most in vitro studies indicate that the concentration of polyphenols required to efficiently scavenge
ROS is generally between 10 and 100 µM. Such concentrations are greater than those reported to be
reached in plasma after ingestion of a polyphenol-rich food. Therefore, it seems that the intracellular
antioxidant action could be explained by a number of other mechanism, which generally require
lower concentrations and do not involve the stoichiometric oxidative consumption of polyphenol
molecules. In this regard, some polyphenols are able to induce the Keap1/Nrf2/ARE pathway
for the transcription of cellular endogenous antioxidant defense. Compared to the classical direct
ROS-scavenging antioxidant mechanism, the Keap1/Nrf2/ARE indirect mechanism of action will be
more efficient, since it requires a lower concentration of polyphenols and does not depend on their
direct stoichiometric consumption.
In the second case, without polyphenol cellular uptake, several studies have demonstrated the
interaction of flavonoids with membrane receptors [20], as well as modifiers of cell membrane fluidity,
microviscosity, order, elasticity and permeability [21], which may explain their biological effects in an
indirect way.
Nevertheless, besides knowing the mechanism of action, it is clear that polyphenol intake may
modulate metabolism and reverse a metabolic inflexibility condition. These compounds are now being
recognized for their ability to modulate the capacity of mitochondria to undergo biogenesis; to control
its membrane potential; and its ETC activity and ATP synthesis. A brief review of related studies is
presented in Table 1.
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Table 1. Described effects of dietary phenolic compounds in mitochondria and metabolic flexibility.
Compound Effect Mechanism Type of Study Reference
Resveratrol
Increased number of
mitochondria in
liver and muscle
SIRT1 and PGC-1α
activation Animal model [22]
Quercetin
Increased mtDNA and
cytochrome c content in
muscle and brain
SIRT1 and PGC-1α
activation Animal model [23]
Epicatechin-rich cocoa Mitochondrial biogenesisstimulation in muscle
SIRT1 and PGC-1α
activation Human study [24]
Coumestrol Increased mitochondrial contentin muscle cells SIRT1 activation Cell culture [25]
Quercetin, kaempferol,
epicatechin
Inhibitors of H2O2 production
by mitochondria
Inhibition of complex
I activity Cell culture [26]
Grape seed
proanthocyanidin extract
Enhanced thermogenic capacity
and improvement in
mitochondrial function in
brown and adipose tissue
Not described Animal model [27]
Anthocyanins
Complex I activity recovery
and increase in the
rate of ATP synthesis
Functioning as
electron carriers in a
similar way as
coenzyme Q1
Isolated
mitochondria [28]
Galangin
Modulation of the
mitochondrial permeability
transition pore
Decreased fluidity of
the mitochondrial
membrane
Isolated
mitochondria [29]
Epigallocatechin Modification in mitochondrialarchitecture AMPKα activation Animal model [30]
In relation to mitochondrial biogenesis, resveratrol has been shown to be an effective inductor of
SIRT1-mediated deacetylation of PGC-1α, activating its transcriptional activity in mice liver and muscle;
which resulted in an increased number of mitochondria in the studied tissues [22]. Similarly, quercetin
is able to induce the expression and activation of SIRT1 and PGC-1α and to increase the content of
mtDNA and cytochrome c in both skeletal muscle and brain [23]. In humans, the administration of
epicatechin-rich cocoa to patients with type 2 diabetes and heart failure, a stimulation in mitochondrial
biogenesis in skeletal muscle, as expressed by an increment in SIRT1-dependent activation of PGC-1α
and as a higher content of porin and mitochondrial complexes I and V, was observed [24].
In relation to the ETC, in aged rats, wine polyphenols totally restored muscle maximal
mitochondrial oxidative capacity, normalizing ROS production in association with enhanced
antioxidant defenses [31]. Coumestrol, found in a variety of legumes, increased the mitochondrial
content in a dose-dependent manner in cultured skeletal muscle cells [25]. Moreover, the protein
expression of ETC components, such as NDUFA9, SDHA, UQCRC2, COX1 and ATP5a, and
transcriptional regulators that are responsible for mitochondrial biogenesis, such as PGC-1α and
NRF-1, were augmented with coumestrol stimulation. Anthocyanidins, water-soluble pigments of
colored berries, fruits and vegetables, can alleviate mitochondrial respiratory dysfunction caused by
inhibition of complex I in human and rat tissues [26,27]. In isolated mitochondria from isquemic hearts,
anthocyanins recovered complex I activity, therefore resulting in an increase in State 3 respiration and
in the rate of ATP synthesis [28]. In this case, the suggested mechanism of action was attributed to its
redox potential, where anthocyanins can function as electron carriers in a similar way as endogenous
coenzyme Q1. Some polyphenols have also been reported to be able to induce mitochondrial
uncoupling and/or to modulate the mitochondrial permeability transition pore (MPTP). In a study
using isolated rat liver mitochondria, at 25–50 µM, the flavonol galangin was able to reduce the ∆Ψm
and stimulate State 4 respiration [29]. The uncoupling effect of the flavonoids has been attributed to
their weak acidic and overall high lipophilic nature, which is consistent with their putative ability to be
protonated in the low-pH external side of the inner mitochondrial membrane, to pass through the lipid
layer and to be de-protonated in the high-pH mitochondrial matrix milieu, thus dissipating the proton
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gradient across the inner mitochondrial membrane [32]. Beyond what exactly are the mechanisms by
which polyphenols induce oxidative phosphorylation uncoupling, several investigators coincide in
that such effects should be associated with a diminished rate of ROS formation through the ETC [33].
Our experience in polyphenols’ effects in insulin resistance suggests that the metabolic effect
of its supplementation will depend greatly on the type of polyphenols. For example, the effects
of epigallocatechin gallate in energy metabolism may be related to its ability to modulate energy
uptake leading to mitochondrial adaptations [30]. Within this experiment, it was observed that the
energy uptake by both gut and different peripheral tissues was reduced, where an increase in AMPKα
was observed and further modifications in mitochondrial architecture; suggesting that the main
effect of this type of polyphenol was a calorie-restriction mimicking one. In the opposite way, soy
phytoestrogenic polyphenols may modulate energy metabolism by the stimulation of estrogen receptor
pathways. Increased levels of estrogen may promote nuclear transcription of NRF-1 and further an
increase in the transcription of nuclear genes that encode mitochondrial proteins involved in oxidative
phosphorylation [34]. Additionally, it has been observed that soy isoflavones may improve insulin
signaling [35], increasing cellular energy uptake capacity. However, at this point, a warning should be
raised, since although in both cases of polyphenol treatments (epigallocatechin gallate and isoflavones),
clinical parameters of insulin resistance and obesity will be improved, and long-term treatment will
lead to different end-points. The reduction of energy uptake will lead to a lower energy production
and, therefore, a reduced oxidative stress status. In the opposite way, an increase in energy uptake and
metabolization will lead to an increase in energy production with the concomitant increase in oxidative
stress. Unpublished observations from our laboratory demonstrate that although soy isoflavones
improve insulin resistance parameters in a high-fat diet, an increase in general protein oxidation was
observed, while the effect of green tea supplementation was a reduction in general protein oxidation.
4. ω-3 Fatty Acids and Mitochondria
Naturally-occurringω-3 long-chain polyunsaturated fatty acids, namely eicosapentaenoic acid
(EPA; 20:5n-3) and docosahexaenoic acid (DHA, 22:6n-3), are now regarded as healthy constituents
of diets for diabetic patients. The metabolic effects of ω-3 fatty acids primarily result from their
interactions with several organ systems. In the liver, hypolipidemic effects are observed due to a
decrease in lipogenesis, a lower formation of triacylglycerols and a lower release of very low density
lipoproteins into circulation, as well as an increase in fatty acid oxidation [36]. In skeletal muscle,
the insulin-sensitizing effect of ω-3 fatty acids could be due to the increased glucose uptake and
utilization [37]. For example, rats fed with ω-3 fatty acids utilize less oxygen for a given twitch
force [38], suggesting that the improvement of mitochondrial efficiency could be either from a greater
content of the electron transfer complexes or from enhanced kinetics of existing proteins. ω-3 fatty
acids probably induce a switch in substrate metabolism, namely by an increase in fat oxidation and a
decrease in carbohydrate oxidation [39,40]. They also affect the development of adipose tissue, as well
as its metabolism and secretory functions [41]. A brief review of studies that observed effects inω-3
fatty acids’ supplementation in mitochondria and/or metabolism is presented in Table 2.
Growing evidence suggest that dietaryω-3 fatty acids have a profound effect on mitochondria
membrane phospholipid composition and, therefore, mitochondria function. Similar to cell membranes,
mitochondrial membranes are rich in phosphatidylethanolamine (PE) and phosphatidylcholine (PC).
However, unlike other membranes in mammalian cells, mitochondrial membranes contain high
levels of cardiolipin, a tetra-acyl phospholipid. Cardiolipin comprises 10%–20% of the mass of
total mitochondrial phospholipids, and its depletion results in severe mitochondrial dysfunction.
Cardiolipin is necessary for the formation of contact sites between inner and outer mitochondrial
membranes, stabilization of essential inner membrane proteins and respiratory complexes and in
mitochondrial apoptotic signaling pathways [42]. Linoleic acid is the main fatty acyl moiety in
cardiolipin, with 60%–80% of cardiolipin being tetralinoleoyl cardiolipin. Possibly, the mechanism
of action of ω-3 fatty acids could be explained by the fact that changing membrane dietary fatty
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acid composition may modify the thickness, stiffness and fluidity of the lipid bilayer. It has been
suggested that DHA is required for the organization and function of membrane proteins. This may be
important in mitochondria, where electron transfer is tightly coupled between the complexes of the
embedded electron transport chain. Furthermore, it has been observed that the unsaturation index
of the mitochondrial membrane in rodents is positively associated with rates of palmitate oxidation.
However, no changes inω-3 incorporation into cardiolipin have been observed, although there was a
strong trend for reductions in both linoleic and arachidonic acid content in cardiolipin followingω-3
supplementation [43].
In humans,ω-3 fatty acids supplementation (3 g for 12 weeks) induced an 8.8- and 3.9-fold increase
in mitochondrial PC and PE fractions, respectively, while DHA incorporation increased 6.4- and
2.9-fold in PC and PE fractions, respectively, while also increasing 2.9-fold in the phosphatidylserine
fraction [43]. However, no differences were found in mitochondrial respiration capacity and kinetics,
and it does not alter the OXPHOS protein content. This could be explained, in part, because despite the
observed changes in membrane composition, no differences in membrane microviscosity and fluidity
were observed [44]. In this study, the change inω-3 fatty acids was at the expense ofω-6 fatty acids
without modifying the content of saturated fatty acids, even in a high saturated fat diet, explaining the
lack of observed effects in membrane fluidity.
Mitochondrial phospholipid remodeling with ω-3 fatty acids is further associated with delayed
Ca2+-induced MPTP opening. Mitochondria determine cell survival through the opening of MPTP,
which occurs under conditions of cell stress, causing mitochondrial depolarization and triggering of cell
death. It was found that dietary supplementation with a mixture of DHA + EPA (70:30) increased the
tolerance of isolated mitochondria to Ca2+-induced MPTP opening [45], with a decrease in hydrogen
peroxide production [46]. The mechanism for greater resistance to Ca2+-induced mitochondrial
permeability transition following ω-3 fatty acids supplementation is not clear. Although, it is
suggested that an increase in DHA membrane content may slow Ca2+ uptake in response to an
extra-mitochondrial upload, since its supplementation did not affect mitochondrial Ca2+ content,
but attenuated the acute increase in mitochondrial Ca2+ following norepinephrine stimulation in
isolated mitochondria from normal rat hearts [47]. This notwithstanding, it is necessary to mention
that the enrichment of the mitochondrial membrane with polyunsaturated fatty acids bears the risk of
lipid peroxidation. For instance, it has been described that DHA hydroperoxides apparently induced
apoptosis and a dose-dependent attenuation of the mitochondrial potential [48].
Table 2. Described effects of dietary phenolic compounds in mitochondria and metabolic flexibility.
Product Effect Mechanism Type of Study Reference
Fish oil Improvement inmitochondrial efficiency
Increased content or
enhanced kinetics of ETC Animal model [38]
Fish oil Reduced body fat mass Stimulation of lipid oxidation Human study [39]
Fish oil Decrease in insulinemia Increased lipid oxidation Human study [40]
DHA + EPA Improve in mitochondrialADP kinetics
Incorporation in mitochondrial
membranes, displacingω-6 species
in several phospholipids population
Human study [44]
DHA + EPA Decrease in H2O2 production
Increased tolerance to Ca2+-induced
MPTP opening
Isolated mitochondria [47]
Fish oil Improvement in ATP production inbrain Improvement in membrane fluidity Animal model [49]
EPA and DHA Increase in ATP and reduction inROS levels in hepatocytes
Increase in the length of
mitochondrial tubes by an increase
in Mfn2 mRNA levels
Cell culture [50]
EPA Restoration of skeletal musclemitochondrial capacity
Increase in coupling efficiency of the
ETC Animal model [51]
The apparent discrepancy between reported findings may be explained by the possibility that
ω-3 fatty acids may enhance mitochondrial function only under conditions where dysfunction is
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evident. Fish oil supplementation, for example, enhanced the respiratory control ratio and significantly
improved the ATP levels in mitochondria from the brains of aged mice [49], where adult control
mice had a significantly reduced activity of the respiration system complexes I, II and IV. These last
authors suggested that fish oil improved mitochondrial function by modulating the expression of
mitochondria-related genes. In in vitro hepatic cell culture, EPA and DHA induced an increase in Mfn2
mRNA levels, where an increase in the length of mitochondrial tubes was observed, increasing ATP
and reducing ROS levels [50]. In another possible mechanism of action, comparing young with old
mice, 10 weeks of EPA supplementation partially restored skeletal muscle mitochondrial capacity by
increasing the coupling efficiency of the mitochondrial electron transport chain [51]. In this study,
although no differences were found on mitochondrial biogenesis or abundance, a reduction in protein
oxidative carbamylation was observed. Since protein carbamylation is catalyzed by myeloperoxidases,
which is most abundant in neutrophils and has been found within skeletal muscle under conditions of
neutrophil infiltration in response to inflammation, the possible anti-inflammatory effects of EPA may
be driving improvements in mitochondrial function.
Finally, the effects on mitochondrial function are reflected in the flexibility of the metabolism. Prior
to metabolic inflexibility, in obesity, fatty acid metabolism is accelerated with possible accumulation
of incomplete oxidation products, which may exacerbate insulin resistance. The accumulation of
short-chain and long-chain acylcarnitines reflects a metabolic block of β-oxidation, when fatty acids are
metabolized only partially. In this sense,ω-3 supplementation improves β-oxidation efficiency, where
a reduction of even side-chain (C > 10) acylcarnitines, aroused in obesity controls, was significantly
reduced. Additionally, several genes involved in carbohydrate metabolism showed significant
changes in expression, such as pyruvate dehydrogenase kinase 4, a regulatory enzyme limiting
oxidation of glucose by inhibiting the pyruvate dehydrogenase complex; fructose-1,6-biphosphatase 2,
a key enzyme of gluconeogenesis catalyzing the hydrolysis of fructose 1,6-biphosphatase to fructose
6-phosphate; and glucose transporter 4, which is essential for the insulin-stimulated glucose uptake in
muscle cells. In regards to lipid metabolism, genes encoding acyl-CoA thioesterase, a mitochondrial
enzyme hydrolyzing medium and long-chain acyl-CoA to free fatty acids and CoASH, carnitine
palmitoyltransferase 1b, the rate-limiting transporter of activated fatty acids for mitochondrial
β-oxidation in the muscle, and CD36 protein, acting as a plasma membrane inducible transporter,
were regulated byω-3 fatty acids [52].
5. Dietary Fiber, Gut Microbiota and Derived Colonic Fermentation Metabolites
and Mitochondria
Dietary fiber is defined as all food matrix components resistant to the action of digestive enzymes
and, therefore, are not absorbed in the small intestine and could serve as substrates for fermentation
by the colonic microbiota. Epidemiological evidence suggests that populations who follow a fiber-rich,
traditional diet are likely to have a lower body weight and improved metabolic parameters than
their Western-diet counterparts. Dietary fiber could play a role in the management of metabolic
syndrome through its ability to control body weight evolution through its effect on satiety; to modulate
glucose homeostasis/insulin sensitivity and to positively affect factors implicated in cardiovascular
diseases. Recent experimental data suggest that the modification of gut peptides (involved in appetite
and glucose homeostasis) could constitute a ‘metabolic relay’, allowing specific dietary fiber to act
on appetite and other components of metabolic syndrome [53]. The efficacy of dietary fiber differs
according to its dietary sources (fruits, legumes or cereals), but also to its specific chemical structure,
responsible for its physical properties (i.e., gel-forming capacity) or for its fermentation capacity in the
lower part of the gut.
The plausible mechanism of action of fiber on mitochondrial function could be derived by its
ability to reduce energy intake by the inhibition of intestinal absorption of nutrients, the neuronal and
satiety effects induced by its fermentation and bulking effect, the colonic fermentation by-products,
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mainly short-chain fatty acids (SCFA), that could serve as substrates for ATP synthesis and by the type
of microbiota and microbiota metabolism.
The first evidence about the role of gut microbiota on the development of obesity came from
studies conducted on germ-free mice (GF-mice) compared to conventionally-raised mice [54]. In basal
conditions, the latter have a 40% higher body fat content than GF-mice, and this phenomenon
was independent of food intake. In a subsequent study, it was observed that GF-mice, fed with a
“high sugar-high-fat Western diet”, do not seem to develop obesity. The main mechanisms explaining
GF resistance to diet-induced obesity are the enhanced fatty acids oxidation, uncoupled with decreased
lipoprotein lipase activity and fatty acids storage [55]. The lean phenotype was associated with
increased skeletal muscle and liver levels of phosphorylated AMPK and its downstream targets
involved in fatty acid oxidation (acetyl-CoA carboxylase; carnitine-palmitoyltransferase). Other
studies have reported specific changes of gut microbiota composition in genetically obese mice,
compared to lean counterparts, showing a 50% reduction in the abundance of Bacteroidetes and a
proportional increase in Firmicutes [56]. These specific changes could contribute to the increased SCFA
production and energy harvest [57]. From another point of view, it is suggested that gut microbial
ecology is to a large extent modulated by diet in humans; a high intake of fat and proteins is associated
with increased levels of Bacteroides, whereas high fiber intake is associated with increased levels of
Prevotella [58,59]. Recently, metagenomic analysis showed that the gut microbiota of responders of a
dietary fiber treatment was enriched in Prevotella copri and had increased potential to ferment complex
polysaccharides [60]. In the same study, the microbiota enriched in Prevotella was transplanted to
germ-free mice in a high-fat diet; compared to non-responder microbiota, the Prevotella-transplanted
mice contained higher amounts of glycogen in the liver. However, it is not clear how and why,
in obese subjects, gut microbiota seems to extract more energy from ingested food. To identify
metabolic pathways associated with obesity, metabolic reconstructions of the “core” microbiome
revealed significant enrichment in phosphotransferase systems involved in microbial processing of
carbohydrates and in genes involved in carbohydrate, lipid and amino acid metabolism [61]. Therefore,
except for the cases of bacterial translocation, the main effects of fiber intake in metabolic inflexibility
may be derived from the actions of colonic fermentation products.
The main colonic bacterial fermentation products of dietary fiber are SCFAs, such as acetate,
propionate and butyrate. SCFAs can be used for de novo synthesis of lipids and glucose, which are the
main energy sources for the host. SCFAs are good candidates for explaining the biological effects of
fiber consumption in metabolic syndrome, since their bioavailability is almost complete, and they can
serve as substrates for obtaining energy in the mitochondria.
Recently, two orphan G-protein-coupled receptors (GPCR), GPR41 and GPR43, were reported to
be activated by SCFAs. For example, in adipose tissue, SCFA-mediated GPR43 activation suppressed
adipose insulin signaling, leading to inhibition of fat accumulation, and unincorporated lipids and
glucose were primarily utilized in muscles where the expression of energy expenditure, glycolysis
and β-oxidation-related genes was increased [62]. In another study, the incorporation of sodium
butyrate (5% wt/wt in a high-fat diet) induced higher energy expenditure and oxygen consumption
during the night in mice. The calorie intake was also higher without a difference in body weight
compared to the control group, suggesting an increase in fatty acid oxidation that was confirmed by
monitoring 14C-labeled palmitic acid, and a 200% increase in 14C-labeled CO2 in butyrate-treated mice
was observed. In the same study, an obesity treatment experiment was performed, where after five
weeks of treatment with butyrate, the obese mice lost 10.2% of their body weight, reduced their fasting
glucose by 30% and their HOMA-IR by 50%. The authors explain the observed effects by PGC-1α
activation properties in brown fat, skeletal muscle and liver [63].
6. Conclusions
There is ample evidence of the positive effects of several classes of polyphenols,ω-3 fatty acids and
dietary fiber on the reversion of a metabolic inflexibility condition. Although the mechanism of action
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is not well establish, in some cases, an indirect interaction with mitochondrial metabolism is expected,
where most of the described studies suggest the activation of NRF-1, AMPKα, SIRT or PGC-1α as the
main mechanism of action. In the case of polyphenols, due to their reduced bioavailability, a direct
interaction with mitochondrial metabolism is not expected. However, indirect activation of pathways
involved in energy metabolism may induce function and morphological changes in mitochondria.
ω-3 fatty acids have been demonstrated to be directly interacting with mitochondria, since their
incorporation in the phospholipids of the mitochondrial membrane is observed. However, their
incorporation does not induce changes in mitochondrial activity, suggesting that the mechanism of
action could be the indirect stimulation of fatty acids’ β-oxidation, possibly by the activation of PPAR
transcriptional factors. Dietary fiber is a bioactive compound for which it is more difficult to explain
its mechanism of action, since it is not absorbed due to its molecular weight, and several fermentation
by-products could be produced during its fermentation in the colon, each one with pleiotropic effects in
metabolism. The most plausible mechanism of action could be due to its energy restriction properties
and the production of SCFAs, which may induce fatty acids’ β-oxidation. In all cases, it should be
taken into account that the main problem in metabolic inflexibility is the accumulation of energy due
to its high intake, and the main treatment objective should be addressed toward a reduction in energy
intake. The use of bioactive compounds, such as the ones included in this review, could facilitate the
treatment, and they should not be considered as complete problem-solving agents.
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